Evidence mapPaperPMID 18597869Full record

ArticleInternational journal of cardiology2009

Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation.

Nan-Lan Huang, Shu-Hui Chiang, Chia-Hsiang Hsueh, Yao-Jen Liang, Yi-Jung Chen, Ling-Ping Lai

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in International journal of cardiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01410604. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01410604 phase4completed

Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial

Ran2007Enrolled31Registered outcomes8Posted comparisons0ConditionsObesityArmsMetformin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 158 citations in OpenAlex.

  1. Trial
  2. Article
  3. The Gut Microbiota-Related Antihyperglycemic Effect of Metformin.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  4. Review
  5. Immunomodulatory Effects of Metformin Treatment in Pregnant Women With PCOS.The Journal of clinical endocrinology and metabolism · 2023 · on this map
    Article
  6. Anti-inflammatory therapy of atherosclerosis: focusing on IKKβ.Journal of inflammation (London, England) · 2023
    Review
  7. Review
  8. Article
  9. A Novel Pyrazolo[3,4-Molecules and cells · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Nan-Lan HuangInstitute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Shu-Hui Chiang
Chia-Hsiang Hsueh
Yao-Jen Liang
Yi-Jung Chen
Ling-Ping Lai
National Taiwan University · TWFu Jen Catholic University · TWNational Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetformin has been reported to reduce cardiovascular complications in diabetic patients. The purpose of the present study was to investigate the anti-inflammatory effects of metformin on endothelial cells and the related molecular mechanisms.

methodsHuman umbilical vein endothelial cells (HUVEC) were used for the experiments. The effects of metformin on TNF-alpha-induced IL-6 production were investigated. Modulation of AMPK and related signal transduction pathways were also performed.

resultsTNF-alpha increased IL-6 secretion by HUVEC in a dose-dependent manner but inhibitors of NF-kappaB abolished the TNF-alpha-induced IL-6 production. Pre-treatment with metformin (100-1000 micromol/L) also inhibited TNF-alpha-induced IL-6 production, phosphorylation of IkappaB kinase (IKK) alpha/beta and IkappaB-alpha degradation. Metformin increased phosphorylation of AMP-activated kinase (AMPK) but wortmannin, a PI3K inhibitor, negated its effects on AMPK phosphorylation and TNF-alpha-induced IkappaB-alpha degradation. AICAR, a direct AMPK activator, had inhibitory effects on TNF-alpha-induced IL-6 production, similar to that of metformin. Transfection of siRNA against alpha1-AMPK eradicated the inhibitory effects of metformin on TNF-alpha-induced IL-6, implying the essential role of AMPK.

conclusionsMetformin had anti-inflammatory effects on endothelial cells and inhibited TNF-alpha-induced IKKalpha/beta phosphorylation, IkappaB-alpha degradation and IL-6 production in HUVEC. This effect was related to PI3K-dependent AMPK phosphorylation.

Indexed as

AMP-Activated Protein KinasesAnti-Inflammatory AgentsAtherosclerosisCells, CulturedEndothelial CellsEnzyme ActivationHumansHypoglycemic AgentsI-kappa B KinaseInterleukin-6MetforminNF-kappa BPhosphatidylinositol 3-KinasesPhosphorylationRNA, Small InterferingSignal TransductionAMP-Activated Protein KinasesAnti-Inflammatory AgentsHypoglycemic AgentsI-kappa B KinaseIL6 protein, humanInterleukin-6MetforminNF-kappa BPhosphatidylinositol 3-KinasesPRKAA1 protein, humanRNA, Small InterferingTumor Necrosis Factor-alpha

Identifiers

PMID18597869
OpenAlexW1988488542

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.